Single pembrolizumab treatment causing profound durable response in a patient with pulmonary pleomorphic carcinoma. (2019)

• Record Type: Journal Article
• Authors: Tokuyasu, Hirokazu; Ishikawa, Soichiro; Sakai, Hiromitsu; Ikeuchi, Tomoyuki; Miura, Hiroshi
• Is Part Of: Respiratory medicine case reports. Volume 28(2019)
• Publication Date: 2019
• Subjects: Durable response -- Non-small cell lung cancers -- Pembrolizumab -- Pulmonary pleomorphic carcinoma -- Single administration -- Treatment-related pneumonitis; Respiratory organs -- Diseases -- Periodicals; Chest -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory System -- Periodicals; Chest -- Diseases; Respiratory organs -- Diseases; Electronic journals; Periodicals; 616.2
• DOI: 10.1016/j.rmcr.2019.100879
• Languages: English
• ISSNs: 2213-0071

Abstract

Abstract: We report a case of a 73-year-old man diagnosed with pulmonary pleomorphic carcinoma who showed profound durable response after a single treatment with pembrolizumab. The patient underwent a diagnostic workup in our hospital due to a hoarseness of voice. Chest computed tomography revealed a massive pulmonary tumor in the left upper lobe and multiple nodules in the both lung fields. Histological examination of a transbronchial lung biopsy specimen revealed pulmonary pleomorphic carcinoma. First-line treatment with pembrolizumab was discontinued after a single administration due to treatment-related pneumonitis. However, durable response has been observed over 17 months to date.